High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: A public-private initiative

European Respiratory Journal

Volumn 40, Issue 6, 2012, Pages 1569-1572

  Villegas, Sonia L ^a,b   Ferro, Beatriz E ^a,b   Perez Velez, Carlos M ^b   Moreira, Cesar A ^c   Forero, Liliana ^c   Martínez, Ernesto ^a   Rastogi, Nalin ^e   Caminero, Jose Antonio ^d,f  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c Programa Control de la Tuberculosis   (Colombia)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e Unite de la Tuberculose et des Mycobacteries   (Guadeloupe)

^f INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; CHILD; COLOMBIA; FEMALE; GENOTYPE; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH; SCHOOL CHILD; SPUTUM SMEAR; TREATMENT FAILURE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COLOMBIA; COMMUNICABLE DISEASE CONTROL; FEMALE; HUMANS; INFECTIOUS DISEASE MEDICINE; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PRIVATE SECTOR; PUBLIC HEALTH; PUBLIC SECTOR; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84871197784     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00018212     Document Type: Letter

References (8)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2010; WHO/HTM/TB/2010.3: 1-3.
2. Garzon MC, Angee DY, Llerena C, et al. Surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs. Biomédica 2008; 28: 319-326.
3. Moreira CA, Hernandez HL, Arias NL, et al. Initial drug resistance as a threat for tuberculosis control: the case of Buenaventura, Colombia. Biomédica 2004; 24: Suppl. 1, 73-79.
4. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva,WHO Press, 2008.WHO/HTM/TB/2008.392; available from http://whqlibdoc.who.int/hq/2008/WHO- HTM-TB-2008.392-eng.pdf Date last updated: 2008; Date last accessed: April 23, 2012.
5. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914. (Pubitemid 27146535)
6. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12: 869-877.
7. World Health Organization. Public-Private Mix for TB Care and Control A toolkit. Geneva, WHO, 2010. WHO/HTM/TB/2010.12; available from www.who.int/tb/careproviders/ppm/PPMToolkit. pdf Date last updated: 2012; Date last accessed: February 8, 2012.
8. Malmborg R, Mann G, Squire SB. A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control. Int J Equity Health 2011; 10: 49.